诊断时社会经济地位影响系统性红斑狼疮的增量直接医疗费用:一项纵向人群研究
该研究基于加拿大不列颠哥伦比亚省行政健康数据库,纳入1996至2010年新诊断的4679例成人SLE患者及23219名匹配非SLE个体,估算诊断后五年内人均年增量直接医疗费用,并评估社会经济地位(SES)的影响。结果显示SLE患者第一年人均直接费用为13038加元,调整后五年人均年增量费用为10078加元(95%CI=2062-32254),低SES患者的增量费用显著高于高SES患者。
要点
- 新诊断SLE患者第一年人均直接费用13038加元,其中61%来自住院。
- 调整后五年人均年增量直接费用为10078加元(95%CI=2062-32254)。
- 低SES患者增量费用显著更高,人均年额外增加1922加元。
核心结论
- 即使在单一支付方、公共资助的医疗体系中,诊断时低SES仍与SLE管理及相关并发症的显著更高直接医疗费用相关。
研究设计与样本
- 基于加拿大不列颠哥伦比亚省行政健康数据库的纵向人群研究,纳入1996至2010年新诊断的4679例成人SLE患者(86%经住院或风湿科医生识别)和23219名按性别、年龄和日历年匹配的非SLE个体。
- 采用两部分广义线性模型估算诊断后五年内人均年增量费用,并评估不同SES组间的差异。
主要发现
- SLE患者诊断后第一年人均直接费用平均为13038加元(2013年加拿大元),其中61%来自住院、23%来自门诊、16%来自药物;非SLE个体平均为2431加元。
- 调整后SLE诊断后五年内人均年增量费用平均为10078加元(95%CI=2062-32254)。
- 低SES患者 predicted 增量住院、门诊和药物费用均显著高于高SES患者,低SES人均年增量费用额外增加1922加元。
- 限制于完整随访五年的个体时观察到相似模式。
临床怎么用
- 临床医生应关注SLE诊断时低SES患者,其增量直接医疗费用显著更高,可能需更积极的费用管理与资源支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the incremental direct medical costs of a population-based cohort of incident systemic lupus erythematosus (SLE) for the first five years after diagnosis, and impact of socioeconomic status (SES) on such incremental costs. METHODS: From the administrative health databases in British Columbia, Canada, we identified all adults with newly-diagnosed SLE from 1996 to 2010 and obtained a sample from the general non-SLE population matched on sex, age, and calendar-year. We captured costs for outpatient encounters, hospitalisations, and dispensed medications. Using two-part generalised linear models, we estimated per-person-year incremental costs of SLE (difference in costs between SLE and non-SLE, controlling for covariates) during the first five years after diagnosis, and assessed differences in incremental costs across SES groups. RESULTS: We included 4679 newly-diagnosed SLE (86% identified from hospitalisations or rheumatologists) and 23,219 non-SLE individuals. Per-person direct costs for SLE in the first year after diagnosis averaged $13,038 (2013 Canadian), with 61% from hospitalisations, 23% from outpatient encounters, and 16% from medications; costs for non-SLE averaged $2,431. Following adjustment, incremental costs of SLE during the first five years after diagnosis averaged $10,078 per-person-year (95% CI=$2062-$32,254). Predicted incremental hospitalisation, outpatient, and medication costs were all significantly-greater for the low-SES patients versus high-SES (additional $1922 per-person-year in incremental costs for low-SES). Similar patterns were observed when restricting to those followed the full five-years after index date. CONCLUSION: Even in a single-payer, publicly-funded healthcare setting, low SES at SLE diagnosis was associated with significantly-greater direct medical costs for the management of SLE and associated complications.
引用
- McCormick N, Marra CA, Sadatsafavi M, et al. Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study. Semin Arthritis Rheum. 2019. PMID: 31358362. doi:10.1016/j.semarthrit.2019.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。